ArabicChineseEnglishFrenchRussianSpanish
WHO home
All WHO This site only
 

Drug resistance

  WHO > Programmes and projects > Drug resistance

Drug Resistance: HIV/AIDS

HIV drug resistance to antiretroviral drugs

- The Global HIV Drug Resistance Surveillance Network

In the developed world, potent combination antiretroviral (ARV) therapy has remarkably reduced HIV-related mortality. Increasing emergence of resistance to ARV drugs could challenge this achievement. As we scale up to reach millions of persons in developing countries, where 95% of all people with HIV live, identifying HIV resistance to ARV drugs and its causes early will be critical to policy makers and programme managers. This information will enable appropriate action to minimize the appearance and spread of resistance and selection of ARV therapy.

Some facts abut antiretroviral

  • No antiretroviral drug is resistance-proof. HIV drug resistance will evolve naturally, when confronted by the selective pressure from drugs or from the immune system.
  • When HIV replication is not fully suppressed, drug resistance results. This situation is frequently linked to non-compliance of ARV therapy.
  • Resistant viruses can spread and affect ARV therapy. Transmission of HIV resistance strains is of increasing concern in countries where ARV is widely used.
  • Resistance can be contained; the likelihood of its occurrence can be reduced or prevented by an appropriate and careful choice of treatment and by monitoring for resistance.

Corporate resources

[an error occurred while processing this directive]